CORV News and Press, Correvio Pharma Corp. From 03/13/19

Correvio Pharma (NASDAQ: CORV ): Q4 GAAP EPS of -$0.18 beats by $0.03 . More news on: Correvio Pharma Corp., Earnings news and commentary, Healthcare stocks news, , Read more ...

Correvio Reports Fourth Quarter and Full Year 2018 Financial Results Canada NewsWire VANCOUVER, March 13, 2019 Company on Track to Resubmit Brinavess NDA in Q2 2019 Mark H.N. Corrigan , MD to Commence CEO Duties on March 14, 2019 Management to Host Conference Call and...

Correvio Announces Amendment To Term Loan With CRG-Managed Funds Canada NewsWire VANCOUVER, March 11, 2019 Amendment Provides for Up To an Additional $10 Million in Debt Funding NASDAQ: CORV   TSX: CORV VANCOUVER , March 11, 2019 /CNW/ - Correvio...

NASDAQ: CORV  TSX: CORV VANCOUVER , March 7, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Correvio management will present at the following upcoming in...

Correvio To Report Fourth Quarter And Full Year 2018 Financial Results On March 13, 2019 Canada NewsWire VANCOUVER, March 6, 2019 NASDAQ: CORV  TSX: CORV Conference Call Scheduled for Wednesday,  March 13, 2019 at 8:00 a.m. Eastern ( 5:00 a.m. Pacific) ...

NASDAQ: CORV  TSX: CORV VANCOUVER , Feb. 21, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Correvio's management team will participate in 1-on-1 meeting...

NASDAQ: CORV   TSX: CORV VANCOUVER , Feb. 7, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced the presentation of clinical data highlig...